Login Register Cart 0
Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Case Report and Literature Review of Multi-drugs Synergy and Targeted Comprehensive Treatment in Advanced Hepatocellular Carcinoma

Author(s): Guanhua Lu, Limin Ou, Mingrong Cao and Min Hu*

Volume 24, Issue 3, 2024

Published on: 18 September, 2023

Page: [368 - 374] Pages: 7

DOI: 10.2174/1568009623666230801093031

Price: $65

Abstract

Background: A 43-year-old female patient was found to have an abnormal liver function, abnormally elevated alpha-fetoprotein and space-occupying lesions in the liver on routine screening. The patient came to our hospital for further diagnosis and treatment.

Case Presentation: Investigations: Laboratory investigations, digital subtraction angiography (DSA) of the hepatic artery, abdominal ultrasound examination, and magnetic resonance imaging (MRI) scan were conducted using pathological staining and immunohistochemistry. Diagnosis: Clinical diagnosis: cT3NxM0. Barcelona clinic liver cancer (BCLC) staging: BCLC stage C. China liver cancer (CNLC) staging: CNLC IIIa.

Discussion: The patient was hospitalized for the first time for transcatheter arterial chemoembolization (TACE) and FOLFOX-based hepatic arterial infusion chemotherapy (HAIC). Then, the second and third hospital admissions were given HAIC based on FOLFOX. Camrelizumab and oncolytic virus were also injected into the liver cancer through the microcatheter in the first three treatments. On the fourth admission, the patient’s indicators were improved, and the tumor shrank. Furthermore, as the patient suffered adverse reactions the first few times, we suspended the treatment of FOLFOX and the oncolytic virus. Before surgical treatment, lenvatinib was used throughout the treatment. On the fifth admission, the patient underwent liver cancer resection.

Conclusion: It proves the value of multiple combination therapy, which can provide guidance for patients with advanced hepatocellular carcinoma that cannot be surgically removed.

« Previous
[1]
Bruix, J; Han, KH; Gores, G; Llovet, JM; Mazzaferro, V Liver cancer: Approaching a personalized care. J Hepatol., 2015, 62(1), S144-1456.
[2]
Bruix, J; Sherman, M Management of hepatocellular carcinoma: An update. Hepatology., 2011, 53(3), 1020-1022.
[http://dx.doi.org/10.1002/hep.24199]
[3]
Zhou, J; Sun, HC; Wang, Z; Cong, WM; Wang, JH; Zeng, MS Guidelines for diagnosis and treatment of primary liver cancer in China. Liver Cancer., 2018, 7(3), 235-260.
[4]
Zhou, J; Sun, H; Wang, Z; Cong, W; Wang, J; Zeng, M Guidelines for the diagnosis and treatment of hepatocellular carcinoma. Liver Cancer., 2020, 9(6), 682-720.
[5]
Chacko, S; Samanta, S. Hepatocellular carcinoma: A life-threatening disease. Biomed Pharmacother., 2016, 84, 1679-1688.
[http://dx.doi.org/10.1016/j.biopha.2016.10.078]
[6]
Villanueva, A. Hepatocellular carcinoma. N Engl J Med., 2019, 380(15), 1450-1462.
[http://dx.doi.org/10.1056/NEJMra1713263]
[7]
Faivre, S; Rimassa, L; Finn, RS Molecular therapies for HCC: Looking outside the box J Hepatol., 2020, 72(2), 342-352.
[8]
EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol., 2018, 69(1), 182-236.
[9]
Yau, T; Tang, VY; Yao, TJ; Fan, ST; Lo, CM; Poon, RT Development of hong kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology., 2014, 146(7), 1691-1700.
[http://dx.doi.org/10.1053/j.gastro.2014.02.032]
[10]
Park, JW; Chen, M; Colombo, M; Roberts, LR; Schwartz, M; Chen, PJ Global patterns of hepatocellular carcinoma management from diagnosis to death: The bridge study. Liver Int., 2015, 35(9), 2155-2166.
[http://dx.doi.org/10.1111/liv.12818]
[11]
Jiang, H; Meng, Q; Tan, H; Pan, S; Sun, B; Xu, R Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer., 2007, 121(2), 416-424.
[http://dx.doi.org/10.1002/ijc.22655]
[12]
Kudo, M.; Ueshima, K.; Ikeda, M.; Torimura, T.; Tanabe, N.; Aikata, H.; Izumi, N.; Yamasaki, T.; Nojiri, S.; Hino, K.; Tsumura, H.; Kuzuya, T.; Isoda, N.; Yasui, K.; Aino, H.; Ido, A.; Kawabe, N.; Nakao, K.; Wada, Y.; Yokosuka, O.; Yoshimura, K.; Okusaka, T.; Furuse, J.; Kokudo, N.; Okita, K.; Johnson, P.J.; Arai, Y. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut., 2020, 69(8), 1492-1501.
[http://dx.doi.org/10.1136/gutjnl-2019-318934] [PMID: 31801872]
[13]
He, M; Li, Q; Zou, R; Shen, J; Fang, W; Tan, G Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs. sorafenib alone for hepatocellular carcinoma with portal vein invasion. JAMA Oncol., 2019, 5(7), 953.
[14]
Lyu, N; Kong, Y; Mu, L; Lin, Y; Li, J; Liu, Y Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol., 2018, 69(1), 60-69.
[15]
Kudo, M.; Matsui, O.; Izumi, N.; Iijima, H.; Kadoya, M.; Imai, Y.; Okusaka, T.; Miyayama, S.; Tsuchiya, K.; Ueshima, K.; Hiraoka, A.; Ikeda, M.; Ogasawara, S.; Yamashita, T.; Minami, T.; Yamakado, K. JSH Consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the liver cancer study group of Japan. Liver Cancer., 2014, 3(3-4), 458-468.
[http://dx.doi.org/10.1159/000343875] [PMID: 26280007]
[16]
Li, Q.J.; He, M.K.; Chen, H.W.; Fang, W.Q.; Zhou, Y.M.; Xu, L. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase III Trial. J. Clin. Oncol., 2021, 2021, O2100608.
[PMID: 34648352]
[17]
Lyu, N; Lin, Y; Kong, Y; Zhang, Z; Liu, L; Zheng, L FOXAI: A phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma GUT.Letter; Comment, 2018, 67(2), 395-396.
[18]
Kudo, M; Finn, RS; Qin, S; Han, KH; Ikeda, K; Piscaglia, F Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet., 2018, 391(10126), 1163-1173.
[http://dx.doi.org/10.1016/S0140-6736(18)30207-1]
[19]
Qin, S.; Ren, Z.; Meng, Z.; Chen, Z.; Chai, X.; Xiong, J.; Bai, Y.; Yang, L.; Zhu, H.; Fang, W.; Lin, X.; Chen, X.; Li, E.; Wang, L.; Chen, C.; Zou, J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol., 2020, 21(4), 571-580.
[http://dx.doi.org/10.1016/S1470-2045(20)30011-5] [PMID: 32112738]
[20]
Wang, K.; Wang, H.; Lv, Y.; Liu, H.; Liu, J.; Zhang, Y. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: A case report. Ann. Palliat. Med., 2021, 10(1), 803-809.
[http://dx.doi.org/10.21037/apm-20-2572] [PMID: 33545802]
[21]
Wei, F; Huang, Q; He, J; Luo, L; Zeng, Y. Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: A short-term prognostic study. Cancer Manag Res., 2021, 13, 4233-4240.
[http://dx.doi.org/10.2147/CMAR.S304820]
[22]
Russell, SJ; Peng, KW; Bell, JC Oncolytic virotherapy. Nat Biotechnol., 2012, 30(7), 658-670.
[23]
Kaufman, HL; Kohlhapp, FJ; Zloza, A Oncolytic viruses: A new class of immunotherapy drugs. NAt Rev Drug Discov., 2015, 14(9), 642-662.
[http://dx.doi.org/10.1038/nrd4663]
[24]
Bommareddy, PK; Shettigar, M; Kaufman, HL Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol., 2018, 18(8), 498-513.
[http://dx.doi.org/10.1038/s41577-018-0014-6]
[25]
Lawler, SE; Speranza, MC; Cho, CF; Chiocca, EA Oncolytic viruses in cancer treatment: A review. JAMA ONCOL., 2017, 3(6), 841-849.
[http://dx.doi.org/10.1001/jamaoncol.2016.2064]
[26]
Boozari, B; Mundt, B; Woller, N; Struver, N; Gurlevik, E; Schache, P Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. GUT., 2010, 59(10), 1416-1426.
[http://dx.doi.org/10.1136/gut.2009.196519]
[27]
Heo, J; Reid, T; Ruo, L; Breitbach, CJ; Rose, S; Bloomston, M Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat Med., 2013, 19(3), 329-336.
[28]
Zhang, H; Li, K; Lin, Y; Xing, F; Xiao, X; Cai, J Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci Transl Med., 2017, 9(404), eaam7996.
[http://dx.doi.org/10.1126/scitranslmed.aam7996]
[29]
He, CB; Lao, XM; Lin, XJ Transarterial chemoembolization combined with recombinant human adenovirus type 5 h101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: A prognostic nomogram study Chin J Cancer., 2017, 36(1), 59.
[30]
Lin, XJ; Li, QJ; Lao, XM; Yang, H; Li, SP Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC CANCER., 2015, 15, 707.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy